Results 71 to 80 of about 28,905 (252)

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung   +8 more
wiley   +1 more source

#NoIDVape: A content analysis of illicit vape messaging in young people's information sources

open access: yesAddiction, EarlyView.
Abstract Background and aims In recent years, the increased prevalence of youth vaping in the United Kingdom (UK) may have coincided with a proliferation in the use of ‘illicit’ (unregulated) vapes. Media or educational content about illicit vaping aimed at young people is scarce and poorly understood.
Eleanor Bray   +5 more
wiley   +1 more source

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

open access: yesAddiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts   +2 more
wiley   +1 more source

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

open access: yesAddiction, EarlyView.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen   +5 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

open access: yesAddiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin   +3 more
wiley   +1 more source

Computer modeling of Cannabinoid receptor type 1

open access: yesITM Web of Conferences, 2018
Cannabinoid receptors are important class of receptors as they are involved in various physiological processes such as appetite, pain-sensation, mood, and memory.
Sapundzhi Fatima   +3 more
doaj   +1 more source

New Perspectives in the Studies on Endocannabinoid and Cannabis: Cannabinoid Receptors and Schizophrenia

open access: yesJournal of Pharmacological Sciences, 2004
Cannabis consumption may induce psychotic states in normal individuals, worsen psychotic symptoms of schizophrenic patients, and may facilitate precipitation of schizophrenia in vulnerable individuals.
Hiroshi Ujike, Yukitaka Morita
doaj   +1 more source

From emergence to replacement: The evolution of 3‐methylmethcathinone (3‐MMC) and its substitutes in the Dutch drug market (2012–2024)

open access: yesAddiction, EarlyView.
Abstract Background and aims The market for new psychoactive substances (NPS) is highly dynamic, with hundreds of substances emerging on the European drug market in the last decade. 3‐methylmethcathinone (3‐MMC), a synthetic cathinone and isomer of mephedrone (4‐MMC), gained popularity in the Netherlands due to its psychostimulant effects and initial ...
Nadia Robert Petronella Wilhelmina Hutten   +4 more
wiley   +1 more source

Muscarinic cannabinoid suppression of excitation, a novel form of coincidence detection

open access: yesPharmacological Research
Δ9-tetrahydrocannabinol (THC), the chief psychoactive ingredient of cannabis, acts in the brain primarily via cannabinoid CB1 receptors. These receptors are implicated in several forms of synaptic plasticity – depolarization-induced suppression of ...
Michaela Dvorakova   +2 more
doaj   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

open access: yesAddiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Home - About - Disclaimer - Privacy